These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33201)

  • 21. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of normal alcohols on intestinal absorption of salicylic acid, sulfapyridine, and prednisolone in rats.
    Hayton WL
    J Pharm Sci; 1975 Sep; 64(9):1450-6. PubMed ID: 241834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of herb-separated moxibustion combined with sulfasalazine enteric-coated tablets for ankylosing spondylitis with cold-dampness obstruction type].
    Tian ZH; Wang XY; Zhang YF; Tian YS
    Zhongguo Zhen Jiu; 2019 Jan; 39(1):44-8. PubMed ID: 30672255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of enteric coating of aspirin tablets on occult gastrointestinal blood loss.
    Howe GB; Champion GD; Corrigan AB; Hewson J; Haski A; Day RO; Paull PD; Graham GG
    Aust N Z J Med; 1977 Dec; 7(6):600-4. PubMed ID: 350214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro susceptibility of diarrhoea producing gram negative enteric bacteria to sulfasalazine, 5-aminosalicylic acid, sulfapyridine and four quinolones. Brief report.
    Andreasen JJ; Andersen LP; Hartzen SH
    APMIS; 1988 Jun; 96(6):568-70. PubMed ID: 2899438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.
    Dew MJ; Ebden P; Kidwai NS; Lee G; Evans BK; Rhodes J
    Br J Clin Pharmacol; 1984 Apr; 17(4):474-6. PubMed ID: 6144318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: A proof of concept study in healthy subjects.
    de Gunzburg J; Ducher A; Modess C; Wegner D; Oswald S; Dressman J; Augustin V; Feger C; Andremont A; Weitschies W; Siegmund W
    J Clin Pharmacol; 2015 Jan; 55(1):10-6. PubMed ID: 25042595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastric retention of enteric-coated sulfasalazine tablets. A complication of gastroduodenal Crohn's disease.
    Harary AM; Gluck CA; Rogers AI
    Dig Dis Sci; 1984 Nov; 29(11):1063-5. PubMed ID: 6149106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oro-caecal transit time in man assessed by the sulfasalazine/sulfapyridine test. Correlation between plasma-saliva appearance of sulfapyridine.
    Dhôte R; Leglise P; Bergmann JF; Conort O; Caulin C
    Fundam Clin Pharmacol; 1992; 6(8-9):383-5. PubMed ID: 1363408
    [No Abstract]   [Full Text] [Related]  

  • 30. Sulfapyridine appearance in plasma after salicylazosulfapyridine. Another simple measure of intestinal transit.
    Kellow JE; Borody TJ; Phillips SF; Haddad AC; Brown ML
    Gastroenterology; 1986 Aug; 91(2):396-400. PubMed ID: 2873075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets.
    Al-Habet SM; Rogers HJ
    Eur J Clin Pharmacol; 1989; 37(4):423-6. PubMed ID: 2598978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine.
    Goldstein PD; Alpers DH; Keating JP
    J Pediatr; 1979 Oct; 95(4):638-40. PubMed ID: 39125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in man.
    Fischer C; Klotz U
    J Chromatogr; 1979 Feb; 162(2):237-43. PubMed ID: 33196
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration.
    Shaffer JL; Houston JB
    Br J Clin Pharmacol; 1985 Apr; 19(4):526-8. PubMed ID: 2859874
    [No Abstract]   [Full Text] [Related]  

  • 35. Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.
    Kuhn UD; Anschütz M; Schmücker K; Schug BS; Hippius M; Blume HH
    Int J Clin Pharmacol Ther; 2010 Jan; 48(1):1-10. PubMed ID: 20040334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absorption of quinidine from an enteric-coated preparation.
    Fremstad D; Nilsen OG; Amlie J; Storstein L; Olsson B; Jacobsen S
    Eur J Clin Pharmacol; 1979 Sep; 16(2):107-12. PubMed ID: 499306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythromycin absorption in healthy volunteers from single and multiple doses of enteric-coated pellets and tablets.
    Hovi T; Josefsson K; Renkonen OV
    Eur J Clin Pharmacol; 1983; 25(2):271-3. PubMed ID: 6628511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Sulfasalazin--enteric-coated tablets or common tablets?].
    Fanø N; Nyfos L
    Ugeskr Laeger; 1989 Nov; 151(46):3088. PubMed ID: 2574512
    [No Abstract]   [Full Text] [Related]  

  • 39. Salazopyrin EN-tabs: an enteric-coated case that is hard to take.
    Drug Ther Bull; 1987 Jul; 25(14):53-5. PubMed ID: 2886326
    [No Abstract]   [Full Text] [Related]  

  • 40. Azo reduction of sulphasalazine in healthy volunteers.
    Houston JB; Day J; Walker J
    Br J Clin Pharmacol; 1982 Sep; 14(3):395-8. PubMed ID: 6127096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.